

Rubraca[®]
(rucaparib) 300 mg
tablets



YOUR SHIELD AGAINST PROGRESSION IN ADVANCED PROSTATE CANCER

Fight for what matters with RUBRACA

With RUBRACA by your side, you can defend against *BRCA*-mutated advanced prostate cancer^{1*}

*RUBRACA treats metastatic castration-resistant prostate cancer, or mCRPC, which is prostate cancer that has spread to other parts of the body (metastatic) and that no longer responds to testosterone-lowering medical or surgical treatment.

BRCA=BReast CAncer gene.

SELECT IMPORTANT SAFETY INFORMATION

What is RUBRACA[®] (rucaparib) used for?

RUBRACA tablets are a prescription medicine used in adults for:

- The treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
 - That has spread to other parts of the body (metastatic), and
 - Has a certain type of inherited (germline) or acquired (somatic) abnormal *BRCA* gene, and you have been treated with certain medicines for your cancer.
- Your healthcare provider will perform a test to make sure RUBRACA is right for you.

It is not known if RUBRACA is safe and effective in children.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket or visit RubracaProstate.com



YOUR SHIELD FOR MOMENTS THAT MATTER

RUBRACA IS HERE FOR THE NEXT STEP OF YOUR TREATMENT JOURNEY

Navigating metastatic castration-resistant prostate cancer (mCRPC) prostate cancer management can be challenging, making treatment decisions difficult. Use this guide to understand why RUBRACA might be the right treatment for you.

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What Warnings should you know about RUBRACA?

RUBRACA tablets may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with RUBRACA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with RUBRACA. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily. Symptoms of low blood cell counts are common during treatment with RUBRACA, but can be a sign of serious problems, including MDS or AML.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket or visit RubracaProstate.com

RUBRACA is a type of drug called a poly (adenosine diphosphate-ribose) polymerase inhibitor, otherwise known as a PARP inhibitor (or PARPi). RUBRACA is used in patients who meet the following requirements¹:

- Cancer has spread to other parts of the body (metastasized)
- Cancer is no longer responding to medical or surgical treatment that lowers testosterone (castration resistant)
- Based on genetic testing, you are positive for one of the *BRCA*, or BReast CAncer, gene mutations (*BRCA1* or *BRCA2*)
 - Having a *BRCA* gene mutation means that you have inherited or acquired a gene that can put you at higher risk for certain cancers, including prostate cancer^{2,3}

BRCA=BReast CAncer gene.

**RUBRACA IS THE ONLY PARPi
THAT HAS BEEN PROVEN
SUPERIOR TO CHEMOTHERAPY¹**


**Rubraca**[®]
(rucaparib) 300 mg
tablets

HOW RUBRACA WORKS^{1,4,5}

RUBRACA is a type of treatment called a PARP inhibitor (PARPi)¹



PARP and *BRCA* are proteins in the body that help repair damaged DNA in cells. While this repair is what healthy cells need to survive, when PARP and *BRCA* repair DNA in cancer cells, it helps them grow and spread. If you have the *BRCA* mutation, your *BRCA*-mutated cancer cells depend on PARP for DNA repair.⁴



A PARP inhibitor like RUBRACA can stop the PARP protein from repairing DNA in cells, including cancer cells.⁴



When damaged DNA cannot be repaired, the cell dies, helping reduce the growth and spread of cancer cells.^{4,5}



YOUR SHIELD FOR MOMENTS THAT MATTER

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What Warnings should you know about RUBRACA?

Before you take RUBRACA, tell your healthcare provider about all of your medical conditions, including if you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of RUBRACA. Do not donate sperm during use and for 3 months after the last dose of RUBRACA.

What other important information should I know about RUBRACA?

Your healthcare provider will do blood tests before and every month during treatment with RUBRACA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with RUBRACA until your blood cell counts improve.

Avoid spending time in sunlight while on RUBRACA since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket or visit RubracaProstate.com

RUBRACA HELPS PATIENTS LIVE LONGER WITHOUT CANCER PROGRESSING¹

Results are from 405 patients with advanced prostate cancer, of which 302 had a *BRCA1/2* gene mutation. Patients were treated with RUBRACA or physician's choice of medication* after previous treatment with any androgen receptor pathway inhibitor and did not receive chemotherapy previously.⁶

11.2
MONTHS

RUBRACA: A median duration of **11.2 months before the cancer showed signs of growth**, called radiographic progression-free survival (rPFS)⁶

Physician's choice showed a median duration of 6.4 months before the cancer grew (rPFS). Physician's choice included:

8.3
MONTHS

Chemotherapy (docetaxel): A median duration of 8.3 months before the cancer grew (rPFS)⁶

4.5
MONTHS

Second-generation ARPI (abiraterone or enzalutamide): A median duration of 4.5 months before the cancer grew (rPFS)⁶

RUBRACA is the ONLY PARPi inhibitor proven to be more effective than chemotherapy in men with advanced prostate cancer and a BRCA mutation^{1,6}

*Physician's choice included a type of chemotherapy (docetaxel) or a second-generation androgen receptor pathway inhibitor (ARPI) (abiraterone or enzalutamide).

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED) What are the side effects of RUBRACA?

The most common side effects of RUBRACA in people with prostate cancer include: tiredness or weakness, muscle and joint pain, nausea, decrease in hemoglobin (anemia), decreased appetite, changes in liver and kidney function tests, constipation, diarrhea, vomiting, low blood cell counts,

IN A SEPARATE STUDY, MEN WHO HAD ALREADY RECEIVED CHEMOTHERAPY SAW A REDUCTION IN DISEASE^{1,7}

Results are from 81 patients who had *BRCA*-mutated advanced prostate cancer and were treated with RUBRACA after previous treatment with any androgen receptor-directed therapy and a taxane-based chemotherapy.⁷

44%

OF PATIENTS ACHIEVED A REDUCTION IN DISEASE, CALLED AN OBJECTIVE RESPONSE RATE⁷

15.5
MONTHS

WAS THE MEDIAN LENGTH OF TIME THE CANCER RESPONDED TO TREATMENT, ALSO KNOWN AS THE MEDIAN DURATION OF RESPONSE⁷

67%

OF PATIENTS SAW AT LEAST A 30% DECREASE IN TUMOR SIZE⁷

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

shortness of breath, swelling in your legs and feet, dizziness, decreased weight, stomach area (abdominal) pain, changes in how food tastes, rash, tingling sensation and numbness, cough, headache, urinary tract infection, bleeding, photosensitivity reaction.

These are not all the possible side effects of RUBRACA. Call your healthcare provider for medical advice about side effects.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket or visit RubracaProstate.com


Rubraca[®]
(rucaparib) 300 mg tablets

RUBRACA IS TAKEN TWICE DAILY¹



RUBRACA's dosing schedule fits into your daily lifestyle

- 2 tablets taken twice a day, 12 hours apart
- Ability to be taken with or without food
- If you miss a dose or vomit, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
- You may be directed to take RUBRACA along with other medications that treat prostate cancer
- Always take RUBRACA as directed by your doctor. Do not stop treatment without speaking with your healthcare team first

Be sure to let your doctor know of any other medications you may be taking, as RUBRACA could interact with other drugs.

RUBRACA may cause side effects¹

The most common side effects reported with RUBRACA include tiredness/weakness, nausea, decrease in hemoglobin (anemia), changes in liver function tests, decreased appetite, rash, constipation, low blood cell counts, vomiting, and diarrhea. RUBRACA can also cause a variety of abnormal results in laboratory tests, such as blood tests. Talk to your doctor about how to interpret laboratory abnormalities.

Your doctor will monitor you to assess how you are responding to treatment, and may make changes to your treatment to help manage your side effects.

ALERT YOUR DOCTOR ABOUT ANY MISSED DOSES OR SIDE EFFECTS YOU EXPERIENCE, AS DOSE CHANGES OR ADJUSTMENTS MAY BE NEEDED

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What other medications might interact with RUBRACA?

RUBRACA can increase the amounts of other medications you may be taking, which can increase the risk of side effects. Tell your healthcare provider about all your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to pharma@fda.gov at 1-800-506-8501.

This information is not comprehensive. How to get more information:

- Talk to your healthcare provider or pharmacist.
- Visit RubracaProstate.com to obtain the FDA-approved product labeling.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket or visit RubracaProstate.com





KEY QUESTIONS TO ASK YOUR DOCTOR

Make sure to ask your doctor questions during treatment with RUBRACA, including:

- 1 What should I expect with RUBRACA?
- 2 What are the potential side effects of RUBRACA, and are there things that can help me manage side effects?
- 3 How often do I have to take RUBRACA?
- 4 Are there activities or tips that can help me stay healthy and cope while receiving prostate cancer treatment?

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What Warnings should you know about RUBRACA?

RUBRACA tablets may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with RUBRACA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with RUBRACA. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily. Symptoms of low blood cell counts are common during treatment with RUBRACA, but can be a sign of serious problems, including MDS or AML.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket or visit RubracaProstate.com



BE PREPARED FOR YOUR APPOINTMENT

Download the Doctor Discussion Guide

The Doctor Discussion Guide includes a list of questions to ask your doctor to help you feel prepared at each appointment.

SCAN THE QR CODE TO DOWNLOAD



RubracaProstate.com

**Rubraca**[®]
(rucaparib) 300 mg tablets

COMMITMENT TO ACCESS AND AFFORDABILITY



QUICKSTART PROGRAM*

Helps you start RUBRACA if you experience coverage delays regardless of income or insurance. If eligible, you may receive RUBRACA in 15-day increments for up to 60 days (2 months) while coverage is pending or until alternate funding resources have been identified and approved



RUBRACA CO-PAY ASSISTANCE PROGRAM**

Pay as little as \$0 if you're an eligible patient with private or commercial insurance who has been prescribed RUBRACA

* Terms & Conditions may apply.

† TERMS & CONDITIONS FOR THE pharma& CO-PAY PROGRAM

- This offer is only available to patients with commercial insurance. The program is not available for patients who receive reimbursement under any federal, state or government-funded insurance programs, including patients who: (i) are enrolled in Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program; (ii) are not using insurance coverage at all; (iii) are enrolled in an insurance plan that reimburses for the entire cost of the drug; or (iv) where product is not covered by patient's insurance
- The value of this program is exclusively for the benefit of patients and is intended to be credited toward patient out-of-pocket obligations, including applicable co-payments, coinsurance, and deductibles. You agree that you are personally responsible for paying any amount of co-pay required after the savings card is applied
- May not be available if your insurance company or health plan implements either an accumulator adjustment or co-pay maximizer program. Patient is responsible for complying with any applicable limitations and requirements of his/her health plan related to the use of the program. The program may not be used if prohibited by a patient's health insurer

Programs to help you get RUBACA

Rubraca[®]
(rucaparib) 300 mg tablets



COVERAGE LINK PROGRAM*

Provides RUBRACA in 15-day increments (up to 90 days) if you are eligible and experiencing a change in commercial insurance status. This includes switching to a new insurer following a job change or switching plans during an employer's annual enrollment period



PATIENT ASSISTANCE PROGRAM (PAP)*

Available if you are eligible and are uninsured or cannot afford medication

ASK YOUR DOCTOR TO COMPLETE THE RUBRACA ENROLLMENT TO GET STARTED TODAY!

- Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. This program may not be combined with any other financial assistance program, free trial, discount, rebate, coupon, or other offer
- Program is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance
- pharma& reserves the right to make eligibility determinations and to rescind, revoke, or amend the program and discontinue support at any time without notice
- For complete information about the Terms & Conditions of this program, including the limitations on use and the amount of assistance, go to www.RubracaProstate.com or call 1-844-779-7707

These Terms & Conditions are effective as of 01/01/2025.

Please see full Terms & Conditions for the Co-Pay Program and all other access programs at www.RubracaProstate.com/resources-and-support/assistance-programs.

SUPPORT FOR YOU & YOUR CARE PARTNERS

Whether a patient or a care partner, it is important to know what to expect during RUBRACA treatment

INCREMENTAL

IncreMENTal is the **only habit-building program** to support patients with prostate cancer and their care partners as they build a healthier lifestyle. **Fully online courses** are available for patients, which include:

- Easy-to-follow **health and wellness tips**
- Personal progress tracking to **help set and reach goals**
- **Comprehensive information** in a digestible format
- New weekly information to **help change habits** step by step



Learn more at
[IncreMENTalADT.com](https://www.incrementaladt.com)

References: **1.** RUBRACA® (rucaparib). Prescribing Information. pharmaand GmbH. 2025. **2.** BRCA gene changes: cancer risk and genetic testing. National Cancer Institute. <https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet> **3.** Referenced with permission from the NCCN Guidelines for Patients® for Prostate Cancer: Advanced Stage. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 1, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. **4.** Messina C, Cattrini Ci, Soldato D, et al. BRCA mutations in prostate cancer: prognostic and predictive implications. *J Oncol.* 2020;4986365. **5.** Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H. Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.

DISCOVER MORE HELPFUL TIPS AND RESOURCES AT [RubracaProstate.com](https://www.RubracaProstate.com)



Care Partner Corner is a **comprehensive resource** for care partners of patients with prostate cancer with tools, education, and encouragement to support them throughout their loved one's diagnosis and treatment journey. Care partners can find:

- **Guidance** to help prioritize their own wellbeing
- **Clear information** about the prostate cancer journey
- **Downloadable resources** to better equip care partners and reduce stress
- **Access to supportive communities** that can help them connect with others going through similar experiences



Learn more at
[CarePartnerCorner.com](https://www.CarePartnerCorner.com)

Biomed Pharmacother. 2020;123:109661. **6.** Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician's choice in metastatic prostate cancer. *N Engl J Med.* 2023;388(8):719-732. **7.** Abida W, Campbell D, Patnaik A, et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. *Eur Urol.* 2023;84:321-330.





**RUBRACA IS HERE TO SUPPORT YOU
AS YOU FACE ADVANCED PROSTATE
CANCER. LEARN MORE AT
RubracaProstate.com**

Rubraca[®]
(rucaparib) 300 mg
tablets

SELECT IMPORTANT SAFETY INFORMATION

What is RUBRACA[®] (rucaparib) used for?

RUBRACA tablets are a prescription medicine used in adults for:

- The treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
 - That has spread to other parts of the body (metastatic), and
 - Has a certain type of inherited (germline) or acquired (somatic) abnormal *BRCA* gene, and you have been treated with certain medicines for your cancer.
- Your healthcare provider will perform a test to make sure RUBRACA is right for you.

It is not known if RUBRACA is safe and effective in children.

What are the side effects of RUBRACA?

The most common side effects of RUBRACA in people with prostate cancer include: tiredness or weakness, muscle and joint pain, nausea, decrease in hemoglobin (anemia), decreased appetite, changes in liver and kidney function tests, constipation, diarrhea, vomiting, low blood cell counts, shortness of breath, swelling in your legs and feet, dizziness, decreased weight, stomach area (abdominal) pain, changes in how food tastes, rash, tingling sensation and numbness, cough, headache, urinary tract infection, bleeding, photosensitivity reaction.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket or visit RubracaProstate.com



© 2026 Tolmar, Inc. All rights reserved. Tolmar and their associated logo is a trademarks of the Tolmar group. Third-party trademarks and product names belong to their respective owners. RUBRACA[®] is a registered trademark of pharma& Schweiz GmbH, used under license by Tolmar.

TPI.2025.eng.5314.v3 01/26